Drugmakers in the US have come out loud and clear outlining actions, including a website for direct access to manufacturers for purchases and patient assistance resources, as early as January 2026 - a public commitment to “American patients and workers”.

Breaking its perceived public silence on tariffs, the Pharmaceutical Research and Manufacturers of America’s (PhRMA) vocal commitment now, comes against the backdrop of a high decibel cross-country discussions on medicine prices. More importantly, it comes in the nick of time as US President Donald Trump’s dateline for a possible tariff announcement — 100 per cent tariffs on drugmakers importing medicines into the US — comes up on October 1.

“PhRMA member companies are making historic investments in US-based manufacturing and infrastruct

See Full Page